Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype

Journal of Virology

Volumn 76, Issue 3, 2002, Pages 1369-1378

  Jing, Qi Feng ^a   Mozdzanowska, Krystyna ^a   Gerhard, Walter ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1Q; HEMAGGLUTININ; HEMAGGLUTININ SPECIFIC MONOCLONAL ANTIBODY; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTIVIRAL ACTIVITY; ARTICLE; COMPLEMENT SYSTEM; CONTROLLED STUDY; IN VITRO STUDY; INFLUENZA VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; SCID MOUSE; VIRUS NEUTRALIZATION;

EID: 0036145303     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.76.3.1369-1378.2002     Document Type: Article

References (39)

1. Neutralization of influenza virus by normal human sera: Mechanisms involving antibody and complement
2. Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies
3. Structure of influenza virus haemagglutinin complexed with a neutralizing antibody
4. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies
5. The structural requirements for complement activation by IgG: Does it hinge on the hinge
6. A model for neutralization of viruses based on antibody coating of the virion surface
7. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype)
8. The classical complement pathway: Activation and regulation of the first complement component
9. Structure and composition of influenza virus. A small-angle neutron scattering study
10. Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies
11. On the structure of polymeric IgM
12. Neutralization of animal viruses
13. Two influenza A virus-specific Fabs neutralize by inhibiting virus attachment to target cells, while neutralization by their immunoglobulin Gs is complex and occurs simultaneously through fusion inhibition and attachment inhibition
14. A haemagglutinin (HA1)-specific Fab neutralizes influenza A virus by inhibiting fusion activity
15. Complement-fixing IgG1 constitutes a new subclass of mouse IgG
16. A complex of influenza hemagglutinin with a neutralizing antibody that binds outside the virus receptor binding site
17. The complement system: Its importance in the host response to viral infection
18. A set of closely related antibodies dominate the primary antibody response to the antigenic site Cb of the A/PR/8/34 influenza virus hemagglutinin
19. A B cell population that dominates the primary response to influenza virus hemagglutinin does not participate in the memory response
20. Inhibitory effects of anti-interleukin 2 receptor and anti-L3T4 antibodies on delayed type hypersensitivity: The role of complement and epitope
21. Modular organization of proteins containing C1q-like globular domain
22. Activation of mouse complement by different classes of mouse antibody
23. The strong positive correlation between effective affinity and infectivity neutralization of highly cross-reactive monoclonal antibody IIB4, which recognizes antigenic site B on influenza A virus haemagglutinin
24. A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro
25. Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection
26. Activation of mouse complement by monoclonal mouse antibodies
27. X-ray crystallography of antibodies
28. Clonal selection and learning in the antibody system
29. The biological effects of IgM hexamer formation
30. Mice can recover from pulmonary influenza virus infection in the absence of class I-restricted cytotoxic T cells
31. Variations in the neutralizing and haemagglutination-inhibiting activities of five influenza A virus-specific IgGs and their antibody fragments
32. Activation of human complement by mouse and mouse/human chimeric monoclonal antibodies
33. C1: Molecular interactions with activating systems
34. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation
35. Monoclonal antibody therapy of B cell lymphoma: Signaling activity on tumor cells appears more important than recruitment of effectors
36. Studies of group B streptococcal infection in mice deficient in complement components C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity
37. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus
38. Structural basis of immune recognition of influenza virus hemagglutinin
39. Clonal variations in complement activation and deposition of C3b and C4b on model immune complexes